Clinical Trial Update: Anlotinib in Cross-line Treatment of NSCLC and SCLC

View source ↗

Summary

This clinical trial update shows that anlotinib is being evaluated for cross-line treatment of advanced non-small cell lung cancer and extensive-stage small cel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: NSCLC (Advanced Non-small Cell Lung Cancer), SCLC, Extensive Stage | Status: NOT_YET_RECRUITING